Hua Medicine ("the Company", HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world’s first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D).
Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook.
Hua Medicine (the "Company", Hong Kong Stock Exchange Stock Code: 2552) announced yesterday a positive profit alert for the first half of the year for the Company together with its subsidiaries. (the "Group").
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
